Literature DB >> 26014931

Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.

Amabel Lapuebla1, Marie Abdallah1, Olawole Olafisoye1, Christopher Cortes2, Carl Urban2, David Landman1, John Quale3.   

Abstract

Imipenem with relebactam was active against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp., including K. pneumoniae carbapenemase (KPC)-producing isolates. Loss of OmpK36 in KPC-producing K. pneumoniae isolates affected the susceptibility of this combination. Enhanced activity was evident against Pseudomonas aeruginosa, including isolates with depressed oprD and increased ampC expression. However, the addition of relebactam to imipenem did not provide added benefit against Acinetobacter baumannii. The combination of imipenem with relebactam demonstrated activity against KPC-producing Enterobacteriaceae and multidrug-resistant P. aeruginosa.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26014931      PMCID： PMC4505292          DOI： 10.1128/AAC.00830-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  β-lactam/β-lactamase inhibitor combinations: from then to now.

Authors:  Kimberly A Toussaint; Jason C Gallagher
Journal:  Ann Pharmacother       Date:  2014-10-31       Impact factor: 3.154

2.  Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration.

Authors:  David Landman; Elizabeth Babu; Neha Shah; Paul Kelly; Olafisoye Olawole; Martin Bäcker; Simona Bratu; John Quale
Journal:  J Antimicrob Chemother       Date:  2012-02-29       Impact factor: 5.790

3.  Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.

Authors:  John Quale; Simona Bratu; Jyoti Gupta; David Landman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp.

Authors:  Neil Woodford; Matthew J Ellington; Juliana M Coelho; Jane F Turton; M Elaina Ward; Susan Brown; Sebastian G B Amyes; David M Livermore
Journal:  Int J Antimicrob Agents       Date:  2006-03-24       Impact factor: 5.283

5.  In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.

Authors:  Elizabeth B Hirsch; Kimberly R Ledesma; Kai-Tai Chang; Michael S Schwartz; Mary R Motyl; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

6.  Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.

Authors:  Simona Bratu; David Landman; Don Antonio Martin; Claudiu Georgescu; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 7.  The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.

Authors:  Patrice Nordmann; Gaelle Cuzon; Thierry Naas
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

8.  Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  David M Livermore; Marina Warner; Shazad Mushtaq
Journal:  J Antimicrob Chemother       Date:  2013-05-21       Impact factor: 5.790

Review 9.  New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Authors:  Sarah M Drawz; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

10.  "Stormy waters ahead": global emergence of carbapenemases.

Authors:  Gopi Patel; Robert A Bonomo
Journal:  Front Microbiol       Date:  2013-03-14       Impact factor: 5.640
View more
  62 in total

1.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 2.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

Review 3.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

Review 4.  [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria].

Authors:  Alexander Mischnik; Christoph Lübbert; Nico T Mutters
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

5.  Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

6.  In 2035, will all bacteria be multiresistant? Yes.

Authors:  George Dimopoulos; Marin H Kollef; Jon Cohen
Journal:  Intensive Care Med       Date:  2016-04-18       Impact factor: 17.440

7.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

8.  Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016.

Authors:  Fiona Senchyna; Rajiv L Gaur; Johanna Sandlund; Cynthia Truong; Guillaume Tremintin; Dietmar Kültz; Carlos A Gomez; Fiona B Tamburini; Tessa Andermann; Ami Bhatt; Isabella Tickler; Nancy Watz; Indre Budvytiene; Gongyi Shi; Fred C Tenover; Niaz Banaei
Journal:  Diagn Microbiol Infect Dis       Date:  2018-10-13       Impact factor: 2.803

9.  Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.

Authors:  Keith S Kaye; Helen W Boucher; Michelle L Brown; Angela Aggrey; Ireen Khan; Hee-Koung Joeng; Robert W Tipping; Jiejun Du; Katherine Young; Joan R Butterton; Amanda Paschke
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 10.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.